Expected Moves

Critical deadline for addressing Biostax's $1.16M debt burden against effectively zero cash reserves.

Management's planned strategic update on clinical assets, evaluated against the broader deregulatory environment under President Trump.

Q1 2027 financial update, likely featuring a going concern warning unless prior restructuring efforts succeed.